Cebus apella, a nonhuman primate highly susceptible to neuroleptic side effects, carries the GLY9 dopamine receptor D3 associated with tardive dyskinesia in humans

Pharmacogenomics Journal

Volumn 3, Issue 2, 2003, Pages 97-100

  Werge, Thomas ^a   Elbaek Z ^a   Andersen, M B ^a   Lundbaek J A ^a   Rasmussen, H B ^a  

^a Sct Hans Hospital   (Denmark)

Author keywords

Adverse effects; Antipsychotic drugs; Dopamine D3 receptor; Dyskinesia; Monkey; Schizophrenia

Indexed keywords

DOPAMINE 3 RECEPTOR; GLYCINE; NEUROLEPTIC AGENT; SERINE;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEBIDAE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; EXPERIMENTAL MODEL; EXTRAPYRAMIDAL SYMPTOM; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; MONKEY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIMATE; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SPECIES DIFFERENCE; TARDIVE DYSKINESIA;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIPSYCHOTIC AGENTS; CEBUS; DYSKINESIA, DRUG-INDUCED; EXONS; HUMANS; POLYMORPHISM, GENETIC; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

ANIMALIA; CEBIDAE; CEBUS APELLA; PRIMATES;

EID: 0037636581     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500152     Document Type: Article

References (25)

1. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982; 39: 473-481.
2. Weinhold P, Wegner JT, Kane JM. Familial occurrence of tardive dyskinesia. J Clin Psychiatry 1981; 42: 165-166.
3. Yassa R, Ananth J. Familial tardive dyskinesia. Am J Psychiatry 1981; 138: 1618-1619.
4. Waddington JL, Youssef HA. The expression of schizophrenia, affective disorder and vulnerability to tardive dyskinesia in an extensive pedigree. Br J Psychiatry 1988; 153:376-381.
5. Rosengarten H, Schweitzer JW, Friedhoff AJ. Possible genetic factors underlying the pathophysiology of tardive dyskinesia. Pharmacol Biochem Behav 1994; 49: 663-667.
6. Muller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001; 104: 375-379.
7. Pickar D, Rubinow K. Pharmacogenomics of psychiatric disorders. Trends Pharmacol Sci 2001; 22: 75-83.
8. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 13: 146-151.
9. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 1996; 93: 1945-1949.
10. Lannfelt L, Sokoloff P, Martres MP, Pilon C, Giros B, Johnson E et al. Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr Genet 1992; 2: 249-256.
11. Dubertret C, Gorwood P, Ades J, Feingold J, Schwartz JC, Sokoloff P. Meta-analysis of DRD3 gene and schizophrenia: ethnic heterogeneity and significant association in Caucasians. Am J Med Genet 1998; 81: 318-322.
12. Lundstrom K, Turpin MP. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 1996; 225: 1068-1072.
13. Dubertret C, Gorwood P, Ades J, Feingold J, Schwartz JC, Sokoloff P. Meta-analysis of DRD3 gene and schizophrenia: ethnic heterogeneity and significant association in Caucasians. Am J Med Genet 1998; 81: 318-322.
14. Steen VM, Lovlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997; 2: 139-145.
15. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R et al. Pharmacogenetics of tardive dyskinesia Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27: 105-119.
16. Ishiguro H, Okuyama Y, Toru M, Arinami T. Mutation and association analysis of the 5′ region of the dopamine D3 receptor gene in schizophrenia patients: identification of the Ala38Thr polymorphism and suggested association between DRD3 haplotypes and schizophrenia. Mol Psychiatry 2000; 5: 433-438.
17. Segman RH, Lerer B. Genetic factors underlying drug induced tardive dyskinesia. In: Lerer B (ed). Pharmacogenetics of Psychotropic Drugs. Cambrigde University Press: Cambridge, 2002.
18. Gunne LM, Barany S. Haloperidol-incluced tardive dyskinesia in monkeys. Psychopharmacology (Berl) 1976; 50: 237-40.
19. Kovacic B, Domino EF. Fluphenazine-incluced acute and tardive dyskinesias in monkeys. Psychopharmacology (Berl) 1984; 84: 310-314.
20. Domino EF. Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review. Psychopharmacology (Suppl) 1985; 2: 217-223.
21. Gunne LM, Barany S. A monitoring test for the liability of neuroleptic drugs to induce tardive dyskinesia. Psychopharmacology (Berl) 1979; 63:195-198.
22. Barany S, Haggstrom JE, Gunne LM. Application of a primate model for tardive dyskinesia. Acta Pharmacol Toxicol (Copenh). 1983; 52:86-89.
23. Peacock L, Gerlach J. New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects. Psychopharmacology 1999; 144: 189-197.
24. Segman RH, Heresco-Levy U, Finkel B, Inbar R, Neeman T, Schlafman M et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 2000; 152:408-413.
25. Segman RH, Ebstein RP, Heresco-Levy U, Gorfine M, Avnon M, Gur E et al. Schizophrenia, chronic hospitalization and the 5-HT2C receptor gene. Psychiatr Genet 1997; 7: 75-78.